Mesoblast (MESO) Given a $14.00 Price Target at Maxim Group
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald set a $20.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Mesoblast from a hold rating to a buy rating and set a $6.25 price objective for the company in a report on Saturday, January 13th. Finally, Oppenheimer set a $16.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $13.54.
Shares of Mesoblast (NASDAQ MESO) traded up $0.09 during trading on Wednesday, reaching $7.60. 58,938 shares of the company were exchanged, compared to its average volume of 83,012. The stock has a market cap of $706.60, a price-to-earnings ratio of -20.54 and a beta of 1.83. Mesoblast has a 1 year low of $4.74 and a 1 year high of $12.50.
TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/mesoblast-meso-given-a-14-00-price-target-at-maxim-group/1905528.html.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.